Scarica l'app Stockscreener
5.71
3.20%
-0.20
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MNKD Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$5.91
Aprire:
$5.88
Volume 24 ore:
1.32M
Relative Volume:
0.36
Capitalizzazione di mercato:
$1.75B
Reddito:
$248.37M
Utile/perdita netta:
$11.74M
Rapporto P/E:
114.20
EPS:
0.05
Flusso di cassa netto:
$18.24M
1 W Prestazione:
+9.81%
1M Prestazione:
-3.52%
6M Prestazione:
+39.54%
1 anno Prestazione:
-3.85%
Intervallo 1D:
$5.715
$5.954
Intervallo di 1 settimana:
$5.03
$6.05
Portata 52W:
$3.3812
$6.51
Mannkind Corp Stock (MNKD) Company Profile
Nome
Mannkind Corp
Settore
Industria
Telefono
818-661-5000
Indirizzo
1 CASPER STREET, DANBURY, CA
Confronta MNKD con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MNKD
Mannkind Corp
|
5.715 | 1.81B | 248.37M | 11.74M | 18.24M | 0.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.69 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
749.62 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
813.59 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
360.48 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
339.19 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Mannkind Corp Stock (MNKD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-24 | Iniziato | Truist | Buy |
| 2025-11-13 | Iniziato | Leerink Partners | Outperform |
| 2025-10-20 | Iniziato | Wells Fargo | Overweight |
| 2025-10-10 | Iniziato | Leerink Partners | Outperform |
| 2025-07-16 | Ripresa | H.C. Wainwright | Buy |
| 2025-04-10 | Iniziato | Mizuho | Outperform |
| 2025-02-10 | Iniziato | Wedbush | Outperform |
| 2024-12-20 | Iniziato | Wells Fargo | Overweight |
| 2024-12-19 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-09-09 | Ripresa | Leerink Partners | Outperform |
| 2024-06-13 | Iniziato | Rodman & Renshaw | Buy |
| 2023-10-10 | Iniziato | Wedbush | Outperform |
| 2021-05-14 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2019-12-24 | Iniziato | Oppenheimer | Outperform |
| 2019-10-25 | Iniziato | Cantor Fitzgerald | Overweight |
| 2019-05-14 | Iniziato | BTIG Research | Buy |
| 2019-03-04 | Iniziato | SVB Leerink | Outperform |
| 2019-02-22 | Iniziato | SVB Leerink | Outperform |
| 2018-02-28 | Downgrade | Maxim Group | Hold → Sell |
| 2017-11-01 | Downgrade | Maxim Group | Buy → Hold |
| 2017-10-10 | Iniziato | H.C. Wainwright | Buy |
| 2017-10-06 | Reiterato | Maxim Group | Buy |
| 2017-08-11 | Iniziato | Maxim Group | Buy |
| 2016-05-10 | Reiterato | Piper Jaffray | Underweight |
| 2016-05-10 | Reiterato | RBC Capital Mkts | Underperform |
| 2016-01-06 | Reiterato | Piper Jaffray | Underweight |
| 2016-01-06 | Reiterato | RBC Capital Mkts | Underperform |
| 2015-11-04 | Downgrade | RBC Capital Mkts | Outperform → Underperform |
| 2015-09-09 | Downgrade | Piper Jaffray | Neutral → Underweight |
| 2015-08-03 | Reiterato | RBC Capital Mkts | Outperform |
| 2015-05-11 | Downgrade | JP Morgan | Neutral → Underweight |
| 2015-05-11 | Reiterato | MLV & Co | Hold |
| 2015-04-16 | Reiterato | RBC Capital Mkts | Outperform |
Mostra tutto
Mannkind Corp Borsa (MNKD) Ultime notizie
Investment Recap: Is MannKind Corporation backed by strong institutional buying - baoquankhu1.vn
Ionis' Dawnzera Gets EU Approval for Hereditary Angioedema - Finviz
Will 2026 FDA Decisions on Afrezza and FUROSCIX Redefine MannKind's (MNKD) Narrative - Yahoo Finance
MRKR Stock Up Nearly 114% in 3 Months: Here's What You Need to Know - Finviz
Short Interest in MannKind Corporation (NASDAQ:MNKD) Grows By 26.1% - MarketBeat
MannKind Corporation (MNKD) Reveals 2026 Growth Drivers - Insider Monkey
MannKind (NASDAQ:MNKD) Shares Down 6.4%Here's What Happened - MarketBeat
Axsome Therapeutics Begins Phase III Study on AXS-14 for Fibromyalgia - Finviz
CG Oncology Stock Rallies Nearly 32% in a Week: Here is Why - Finviz
Evaluating MannKind (MNKD) Valuation After Recent Share Price Swings And Long Term Return Profile - Yahoo Finance
TG Therapeutics Stock Rises 7% on Strong Q4 & 2025 Preliminary Results - Finviz
MannKind (NASDAQ:MNKD) Raised to Strong-Buy at Zacks Research - MarketBeat
MannKind (MNKD) Upgraded to Strong Buy: Here's What You Should Know - Yahoo Finance
Deltec Asset Management LLC Takes $3.89 Million Position in MannKind Corporation $MNKD - MarketBeat
MannKind Corporation (NASDAQ:MNKD) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Insider Sell: Stuart Tross Sells 47,006 Shares of MannKind Corp (MNKD) - GuruFocus
Mannkind’s chief people officer sells $297k in stock By Investing.com - Investing.com Australia
Mannkind’s chief people officer sells $297k in stock - Investing.com
MannKind Corp stock hits 52-week high at 6.33 USD By Investing.com - Investing.com Nigeria
Pharma news weekly roundup - The Pharma Letter
Is MannKind Corporation stock affected by interest rate hikesMarket Trend Review & Consistent Profit Alerts - ulpravda.ru
How MannKind Corporation stock reacts to Fed rate cutsJuly 2025 Snapshot & Safe Swing Trade Setups - ulpravda.ru
Why MannKind Corporation stock is favored by top institutions2025 Biggest Moves & High Yield Equity Trading Tips - ulpravda.ru
Merck Looks To Buy Cancer Drugmaker Revolution Medicines: Report - Stocktwits
Boeing’s CEO Tells Staff ‘Important Work Ahead’ To Continue Its Turnaround: Report - Stocktwits
MannKind Rallies On Optimism Of Two Imminent Product Launches: Analyst Sees ‘Multiple Headwinds’ For Stock In 2026 - Stocktwits
How MannKind Corporation stock reacts to global recession fears2025 Volatility Report & Risk Managed Trade Strategies - Улправда
MannKind stock jumps on 2026 catalysts - Investing.com
Can MannKind Corporation stock deliver surprise earnings beatInsider Buying & Advanced Technical Analysis Signals - ulpravda.ru
MannKind Corp stock hits 52-week high at 6.33 USD - Investing.com
MannKind outlines 2026 growth drivers with key FDA decisions ahead - Investing.com
MannKind Provides Business Updates and 2026 Growth Drivers - Yahoo Finance
Leerink Partners Slashes MannKind Corporation’s (MNKD) Price Target to $7, Keeps a Buy Rating - MSN
Voya Investment Management LLC Sells 480,182 Shares of MannKind Corporation $MNKD - MarketBeat
Calamos Advisors LLC Acquires New Position in MannKind Corporation $MNKD - MarketBeat
MannKind Corp Is Suddenly Everywhere – Is MNKD the Next Sleeper Stock You’ll Regret Ignoring? - AD HOC NEWS
MannKind Corporation (MNKD) Secures FDA Approval for FUROSCIX Pediatric Use, Expanding Reach In Heart, Kidney Disease Care - Finviz
12 Best NASDAQ Stocks to Buy in 2026 - Insider Monkey
MannKind (MNKD) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
MNKD (MannKind) ROCE % : 17.64% (As of Sep. 2025) - GuruFocus
Even though MannKind (NASDAQ:MNKD) has lost US$61m market cap in last 7 days, shareholders are still up 80% over 5 years - Yahoo Finance
180 Wealth Advisors LLC Increases Stock Position in MannKind Corporation $MNKD - MarketBeat
How Pediatric FUROSCIX Expansion And New Patents At MannKind (MNKD) Has Changed Its Investment Story - simplywall.st
MannKind Stock Slips Despite FDA Clearing Pediatric Use Of Heart Failure Drug — What’s Spooking Investors? - Stocktwits
Is MannKind Stock a Buy or Sell After the CEO Sold Nearly 66,000 Shares? - Yahoo Finance
Is MannKind Stock a Buy or Sell After the CEO Sold Nearly 66,000 Shares? - The Motley Fool
MannKind stock slips despite FDA clearing pediatric use of heart failure drug — what’s spooking investors? - MSN
FDA approves FUROSCIX for pediatric patients weighing 43kg or more By Investing.com - Investing.com South Africa
FDA approves FUROSCIX for pediatric patients weighing 43kg or more - Investing.com
MannKind Corporation Announces FDA Approval of FUROSCIX® for Pediatric Use and Patent Issuance for FUROSCIX ReadyFlow™ Autoinjector - Quiver Quantitative
Shot for fluid buildup could help kids and work at home in 10 seconds - Stock Titan
Mannkind Corp Azioni (MNKD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
4.38%
1.95%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):